English 
搜索
Hebei Lansheng Biotech Co., Ltd. ShangHai Yuelian Biotech Co., Ltd.

Nanjing Redsun predicts 2016 revenue at USD664.4 millionqrcode

Mar. 17, 2017

Favorites Print
Forward
Mar. 17, 2017
By Think Real - Nanjing Redsun Co., Ltd. (Nanjing Redsun) published its 2016 performance report, according to which the company’s revenue in the whole year would be USD664.4 million, increasing slightly, by 0.04% year on year. Its operation profit and net profit were USD31.7 million and USD22.8 million, increasing by 0.62% and decreasing 14.1% year on year respectively.
 
The following are reasons behind the good performance of the company in 2016:
1.   It expanded the production lines of fluorine chlorine pyridine, chlorine pyridine, chlorpyrifos and diquat.
2.   The sales volume of its paraquat GW grew, resulting in the situation of “supply falls behind demand”.
3.   It successfully developed the biochemical industrial chain of L-glufosinate-ammonium with independent intellectual property right.
4.   It is gradually realizing the industrialization research of new fungicides like pyraclostrobin, prothioconazole and prochloraz.
5.   It integrated the domestic paraquat industry by acquiring the 70% shares of the producer Shandong Kexin Bio-Chemistry Co., Ltd.
 
Source: Think Real

0/1200

More from AgroNewsChange

Hot Topic More

Subscribe Comment

Subscribe 

Subscribe Email: *
Name:
Mobile Number:  

Comment  

0/1200

 

NEWSLETTER

Subscribe China Special Biweekly to send news related to your mailbox